reports
EQS-News: Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennu...
Emittent / Herausgeber: Mainz BioMed N.V. / Schlagwort(e): Konferenz Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 07.05.2024 / 14:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Mainz Biomed präsentiert Ergebnisse der Darmkrebsfrüherkennungsstudie eAArly DETECT auf der Digestive Disease Week 2024 Die Studiendaten von eAArly DETECT belegten eine Sensitivität für Darmkrebs von 97% mit einer Spezifität von 97% und eine Sensitivität für fortgeschrittene Adenom...
EQS-News: Mainz Biomed to Present Results of Colorectal Cancer Screeni...
Issuer: Mainz BioMed N.V. / Key word(s): Conference Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. 07.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELE...
EQS-News: Mynaric selected by Rocket Lab for Space Development Agency’...
EQS-News: Mynaric AG / Key word(s): Incoming Orders Mynaric selected by Rocket Lab for Space Development Agency’s Tranche 2 Transport Layer – Beta Program 07.05.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Laser Communications Manufacturer Expands Customer Roster LOS ANGELES, May 7, 2024 – (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced that it has been selected by Rocket Lab USA, Inc (NASDAQ: RKLB) to supply free space optical ...
EQS-News: Mynaric wurde von Rocket Lab für das Tranche 2 Transport Lay...
EQS-News: Mynaric AG / Schlagwort(e): Auftragseingänge Mynaric wurde von Rocket Lab für das Tranche 2 Transport Layer - Beta Programm der Space Development Agency ausgewählt 07.05.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hersteller für Laserkommunikation erweitert Kundenstamm LOS ANGELES, 7. Mai 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), ein führender Großserienanbieter von kosteneffektiven und in skalierbaren Mengen produzierten Laserkommunikationsprodukten, gab heute bekannt, dass es von Rocket Lab USA, Inc. (...
Hitachi Energy supports long-term operation of largest HVDC-connected ...
Hitachi Energy supports long-term operation of largest HVDC-connected wind energy project in U.S. Multi-year agreement provides service solutions to the SunZia Transmission Project, linking New Mexico’s wind farms to Arizona’s grid, increasing renewable energy to Western States Zurich, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Hitachi Energy announced that it has signed a multi-year agreement with Pattern Energy to support its high-voltage direct current (HVDC) technologies for the SunZia Transmission Project. The link will connect the 3,515-megawatt (MW) SunZia Wind project in New ...
Interim report for Q2 and H1 2023/24 (the period 01.10.2023 - 31.03.20...
Interim report for Q2 and H1 2023/24 (the period 01.10.2023 - 31.03.2024) Nørresundby, Denmark, 7 May 2024Announcement no. 25/2024 Q2 MEETS EXPECTATIONS, WITH GROWING ORDERS AND SALES, IN A MARKET, WHERE CUSTOMER INVENTORIES ARE NORMALIZING AND REORDERING IS BEGINNING TO PICK UP. “The results for Q2 are in line with our expectations for the quarter, reaching sales of DKK 125 million and trimming inventory by DKK 8 million during the quarter. In Q2, we furthermore see an increase in our order intake, indicating a shift towards more typical market dynamics, characterized by shorter ...
Bridger Aerospace Announces Schedule for its First Quarter 2024 Earnin...
Bridger Aerospace Announces Schedule for its First Quarter 2024 Earnings Release and Conference Call BELGRADE, Mont., May 07, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it will release financial results for the first quarter ended March 31, 2024 on Monday, May 13, 2024 after the market close. Management will conduct an investor conference call on Monday, May 13, 2024, at 5:00 p.m. Eastern Time (3:00 p.m. Mountain Time) to discus...
Form 8.3 - UK Commercial Property REIT Limited
Form 8.3 - UK Commercial Property REIT Limited 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securitie...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® ...
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024 Digestive Disease Week Conference (DDW), to be held May 18-2...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study e...
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D.C. from May ...
Zscaler Joins Forces with Google to Offer Unparalleled Zero Trust Data...
Zscaler Joins Forces with Google to Offer Unparalleled Zero Trust Data and Threat Protection Enterprises can now Ensure Secure, Remote Access to Private Web Apps across devices and locations with Zscaler and Google Chrome Enterprise SAN JOSE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ZS), the leader in cloud security, has collaborated with Google on a joint zero trust architecture with Chrome Enterprise. This powerful combination brings the power of Zscaler Private Access™ (ZPA) enabling zero trust secure access to private applications to anyone across different locations and d...
Great Lakes Reports First Quarter 2024 Results
Great Lakes Reports First Quarter 2024 Results First quarter net income of $21.0 millionFirst quarter adjusted EBITDA of $42.9 millionDredging backlog of $879.4 million at March 31, 2024 HOUSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) (Nasdaq: GLDD), the largest provider of dredging services in the United States, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Revenue was $198.7 millionTotal operating profit was $31.5 millionNet income was $21.0 millionAdjusted ...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and...
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDAData presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell linesSeveral clinical data updates expected in 2H 2024 FORT LEE, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focus...
Alphawave IP Group: 1 director
A director at Alphawave IP Group maiden bought 100,000 shares at 117p and the significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
GCM Grosvenor Reports First Quarter 2024 Earnings Results
GCM Grosvenor Reports First Quarter 2024 Earnings Results CHICAGO, May 07, 2024 (GLOBE NEWSWIRE) -- GCM Grosvenor (Nasdaq: GCMG) today reported its results for the first quarter 2024, which have been posted to the Public Shareholders section of GCM Grosvenor’s website at . A conference call to discuss GCM Grosvenor’s financial results will be held today, Tuesday, May 7, 2024, at 10:00 a.m. ET. The call will be accessible via public webcast from the Public Shareholders section of GCM Grosvenor’s website at , and a replay of the live broadcast will be available on the website soon after th...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results an...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the q...
Cogent Biosciences Reports First Quarter 2024 Financial Results
Cogent Biosciences Reports First Quarter 2024 Financial Results SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 1Q 2024 with $435.7 million in cash, sufficient to fund operations into 2027 WALTHAM, Mass. and BOULDER, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and announced financial results for the first quarter en...
Biora Therapeutics to Report First Quarter 2024 Financial Results and ...
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets. Conference Call and Webcast Information Date: Wednesday, May 15, 2024 Time: 4:30 PM Eastern time / 1:30 PM Pacific tim...
Oxford Lane Capital Corp. Schedules Fourth Fiscal Quarter Earnings Rel...
Oxford Lane Capital Corp. Schedules Fourth Fiscal Quarter Earnings Release and Conference Call for May 14, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCM) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) announced today that it will hold a conference call to discuss its fourth fiscal quarter earnings on Tuesday, May 14, 2024 at 4:00 PM ET. The toll free dial-in number is 1-833-470-1428, access code number 548622. There will be a recorded replay of the call available for 30 days afte...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Dev...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.